Partial motor epilepsy

Summary

Partial motor epilepsy (MONDO:0006891) is a disease. A subtype of focal epilepsy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	partial motor epilepsy
Mondo ID	MONDO:0006891
EFO	EFO:1001089
MeSH	D020938
DOID	DOID:3327
SNOMED CT	128612007
UMLS	C0016399
MedGen	5237
Is cancer (heuristic)	no

Disease family

This is a subtype of focal epilepsy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › epilepsy › focal epilepsy › partial motor epilepsy

Related subtypes (8): frontal lobe epilepsy, simple partial epilepsy, complex partial epilepsy, partial sensory epilepsy, familial partial epilepsy, combined generalized and focal epilepsy, variable-age onset focal epilepsy syndrome, childhood-onset self-limited focal epilepsy syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Carisbamate	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 0.